Oral LD50 is 1189-2100 mg/kg in mice, rats and rabbits.
Dapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is found in ophthalmic solutions used to reverse mydriasis after an eye examination.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Testosterone undecanoate | Testosterone undecanoate may increase the hypertensive activities of Dapiprazole. |
| Cyclobenzaprine | The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dapiprazole. |
| Metoclopramide | The risk or severity of sedation can be increased when Metoclopramide is combined with Dapiprazole. |
| Lasmiditan | The risk or severity of adverse effects can be increased when Lasmiditan is combined with Dapiprazole. |
| Ziprasidone | The risk or severity of adverse effects can be increased when Dapiprazole is combined with Ziprasidone. |
| Haloperidol | The risk or severity of CNS depression can be increased when Haloperidol is combined with Dapiprazole. |
| Ziconotide | The risk or severity of CNS depression can be increased when Dapiprazole is combined with Ziconotide. |
| Fluoxetine | Dapiprazole may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine. |
| Oliceridine | The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Dapiprazole is combined with Oliceridine. |
| Alfuzosin | Dapiprazole may increase the hypotensive activities of Alfuzosin. |
| Ropeginterferon alfa-2b | The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Dapiprazole. |
| Daridorexant | The risk or severity of CNS depression can be increased when Dapiprazole is combined with Daridorexant. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole. |
| Avanafil | Dapiprazole may increase the hypotensive activities of Avanafil. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Dapiprazole. |
| Midazolam | The risk or severity of sedation and CNS depression can be increased when Midazolam is combined with Dapiprazole. |
| Tretinoin | The risk or severity of elevated intracranial pressure can be increased when Dapiprazole is combined with Tretinoin. |
| Ganaxolone | The risk or severity of sedation, somnolence, and CNS depression can be increased when Dapiprazole is combined with Ganaxolone. |
| Zuranolone | The risk or severity of CNS depression can be increased when Zuranolone is combined with Dapiprazole. |
| Iloperidone | The risk or severity of hypotension can be increased when Dapiprazole is combined with Iloperidone. |